Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $28.00 to $27.00. They now have a "buy" rating on the stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $23.00 to $22.00. They now have a "market outperform" rating on the stock.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript [Yahoo! Finance]